Kilter Group’s NovoCure NVCR Stock Holding History

Kilter Group’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-9	Closed	-$161	–	1293
2025 Q2	$161	Buy	+9	New	+$157	﹤0.01%	1124

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Kilter Group's NVCR Position: Q3 2025 in Review

Kilter Group sold out of NovoCure (NVCR) in Q3 2025, closing a stake of 9 shares — an estimated $161 sold.

Kilter Group first reported a position in NVCR in Q2 2025 and held it in 1 quarter. The position peaked at $161 in Q2 2025. 244 funds tracked by Wall St. Rank hold NVCR as of Q3 2025.

Kilter Group reported no remaining NovoCure position as of Q3 2025 after selling out during the quarter.
Kilter Group sold 9 NovoCure shares in Q3 2025, an estimated $161.
Kilter Group first reported a position in NovoCure in Q2 2025 and held it in 1 quarter.
Kilter Group's NovoCure position peaked at $161 in Q2 2025.
244 funds tracked by Wall St. Rank held NovoCure as of Q3 2025.

Based on Kilter Group's 13F filing for Q3 2025, filed 6 Feb 2026.